Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)

NCT02393417 is registered in ClinicalTrials.gov with Nielsen BioSciences, Inc. as lead sponsor.

NCT NCT02393417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02393417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Lead sponsor
Nielsen BioSciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2015
Completion date
March 31, 2018
Enrollment
243 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

warts